Approximately 60% of HER2-negative metastatic breast cancers display low levels of HER2, as indicated by an immunohistochemical (IHC) score of either 1+ or 2+, along with negative in situ hybridization (ISH) results (44, 45). This evidence concerns the gene ERBB2 and breast carcinoma.